{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:58:52Z","timestamp":1792619932805,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":580,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1124\/jpet.122.001449","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T18:35:40Z","timestamp":1680287740000},"page":"193-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy"],"prefix":"10.1016","volume":"385","author":[{"given":"Takashi","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroe","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kajita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Miyanohana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001449_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/NSS.S103467","article-title":"New developments in the management of narcolepsy","volume":"9","author":"Abad","year":"2017","journal-title":"Nat Sci Sleep"},{"key":"10.1124\/jpet.122.001449_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0960-894X(02)00851-X","article-title":"Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B","volume":"13","author":"Asahi","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.122.001449_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11940-016-0429-y","article-title":"Management of narcolepsy","volume":"18","author":"Barateau","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"10.1124\/jpet.122.001449_bib4","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.neuroscience.2009.04.007","article-title":"Feeding-elicited cataplexy in orexin knockout mice","volume":"161","author":"Clark","year":"2009","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.122.001449_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0165-6147(99)01351-6","article-title":"Partial agonists and G protein-coupled receptor desensitization","volume":"20","author":"Clark","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.122.001449_bib6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/jcph.143","article-title":"Electroencephalogram effects of armodafinil: comparison with behavioral alertness","volume":"53","author":"Conrado","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.122.001449_bib7","doi-asserted-by":"crossref","first-page":"16726","DOI":"10.1074\/jbc.M111.223537","article-title":"Temporal profiling of orexin receptor-arrestin-ubiquitin complexes reveals differences between receptor subtypes","volume":"286","author":"Dalrymple","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.122.001449_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001449_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients","volume":"119","author":"Evans","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001449_bib10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/sleep\/26.8.953","article-title":"Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog","volume":"26","author":"Fujiki","year":"2003","journal-title":"Sleep"},{"key":"10.1124\/jpet.122.001449_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.1c00626","article-title":"Discovery of TAK-925 as a potent, selective, and brain-penetrant orexin 2 receptor agonist","volume":"13","author":"Fujimoto","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.122.001449_bib12","first-page":"349","article-title":"Mechanisms of modafinil: a review of current research","volume":"3","author":"Gerrard","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1124\/jpet.122.001449_bib13","first-page":"RA177","article-title":"Modafinil for narcolepsy: systematic review and meta-analysis","volume":"16","author":"Golicki","year":"2010","journal-title":"Med Sci Monit"},{"key":"10.1124\/jpet.122.001449_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2202-14-90","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Gotter","year":"2013","journal-title":"BMC Neurosci"},{"key":"10.1124\/jpet.122.001449_bib15","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.yexcr.2012.04.015","article-title":"OX2R activation induces PKC-mediated ERK and CREB phosphorylation","volume":"318","author":"Guo","year":"2012","journal-title":"Exp Cell Res"},{"key":"10.1124\/jpet.122.001449_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"key":"10.1124\/jpet.122.001449_bib17","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001449_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173464","article-title":"Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model","volume":"220","author":"Ishikawa","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001449_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tins.2007.05.001","article-title":"Human gamma-frequency oscillations associated with attention and memory","volume":"30","author":"Jensen","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.122.001449_bib20","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1152\/jn.1991.66.6.1902","article-title":"Hyperpolarization-activated inward current in histaminergic tuberomammillary neurons of the rat hypothalamus","volume":"66","author":"Kamondi","year":"1991","journal-title":"J Neurophysiol"},{"key":"10.1124\/jpet.122.001449_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.122.001449_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001449_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J Comp Neurol"},{"key":"10.1124\/jpet.122.001449_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5664\/jcsm.6494","article-title":"Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy","volume":"13","author":"Maski","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"10.1124\/jpet.122.001449_bib25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1460-9568.2005.04238.x","article-title":"The unilateral 6-OHDA rat model of Parkinson\u2019s disease revisited: an electromyographic and behavioural analysis","volume":"22","author":"Metz","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.122.001449_bib26","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.122.001449_bib27","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1523\/JNEUROSCI.0499-13.2013","article-title":"Role of the medial prefrontal cortex in cataplexy","volume":"33","author":"Oishi","year":"2013","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.122.001449_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cellsig.2017.01.024","article-title":"GPCR desensitization: acute and prolonged phases","volume":"41","author":"Rajagopal","year":"2018","journal-title":"Cell Signal"},{"key":"10.1124\/jpet.122.001449_bib29","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","article-title":"CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions","volume":"57","author":"Ripley","year":"2001","journal-title":"Neurology"},{"key":"10.1124\/jpet.122.001449_bib30","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41386-018-0168-8","article-title":"TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects","volume":"44","author":"Sako","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.122.001449_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/jpet.122.001449_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001449_bib33","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001449_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5665\/sleep\/32.1.111","article-title":"A consensus definition of cataplexy in mouse models of narcolepsy","volume":"32","author":"Scammell","year":"2009","journal-title":"Sleep"},{"key":"10.1124\/jpet.122.001449_bib35","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","article-title":"Conditional ablation of orexin\/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function","volume":"34","author":"Tabuchi","year":"2014","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.122.001449_bib36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"10.1124\/jpet.122.001449_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently approved and upcoming treatments for narcolepsy","volume":"34","author":"Thorpy","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1124\/jpet.122.001449_bib38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/pr.109.001321","article-title":"Orexin\/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system","volume":"61","author":"Tsujino","year":"2009","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.122.001449_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2014.04.007","article-title":"Biased ligands at G-protein-coupled receptors: promise and progress","volume":"35","author":"Violin","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.122.001449_bib40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.neuro.24.1.429","article-title":"To eat or to sleep? Orexin in the regulation of feeding and wakefulness","volume":"24","author":"Willie","year":"2001","journal-title":"Annu Rev Neurosci"},{"key":"10.1124\/jpet.122.001449_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172794","article-title":"TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice","volume":"187","author":"Yukitake","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001449_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1254\/jphs.92.259","article-title":"Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins","volume":"92","author":"Zhu","year":"2003","journal-title":"J Pharmacol Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524004476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524004476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:29:11Z","timestamp":1739971751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524004476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0022356524004476"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001449","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}